

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 5405-252		Serial No. 10/008,062	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				Applicants: David Rizzieri et al.			
				Filing Date October 19, 2001		Group 1642	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AMH	1.	4,474,893	10/02/84	Reading	436	547	07/01/81
	2.	4,676,980	06/30/87	Segal et al.	424	85	19/23/85
✓	3.	4,816,567	03/28/89	Cabilly et al.	530	387	04/08/83
✓	4.	5,624,659	04/29/97	Bigner et al.	424	1.49	02/22/95
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AMH	5.	Aeschlimann et al., <i>Identification of Gln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes</i> , J Biol Chem., 267:11316-21 (1992).					
✓	6.	Akabani et al., <i>Dosimetry of ¹³¹I-Labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors</i> , J Nucl Med., 40:631-638 (1999).					
AMH	7.	Back et al., <i>Tenascin expression in activated lymphatic cells and gastrointestinal tracts</i> , Verh Dtsch Ges Pathol (1996) 80:326 (in German) (with English abstract).					
AMH	8.	Bell WR, <i>The fibrinolytic system in neoplasia</i> , Sem Throm Hemostat., 22:459-478 (1996).					
AMH	9.	Bigner et al., <i>Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial of results</i> , J Clin Oncol, 16:2202-2212 (1998).					
	10.	Birchall et al., <i>A microcomputer algorithm for solving first-order compartmental involving recycling</i> , Health Physics, 56:857-868 (1989).					
✓	11.	Bourdon et al., <i>Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody</i> , Cancer Res, 43:2796-2805 (1983).					

EXAMINER Amith HarrisDATE CONSIDERED 6/28/2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 5405-252	Serial No. 10/008,062
LIST OF DOCUMENTS CITED BY APPLICANT			
(Use several sheets if necessary)			
O P E R A T I O N S M A R 6 7 2002 P A T E N T & T R ADE M A R K O F F I C E		Applicants: David Rizzieri et al.	
		Filing Date October 19, 2001	Group 162
12.	Broll et al., <i>Expression of tenascin in tumors of the esophagus, small intestine and colorectum</i> , Gen Diag Pathol, 141:111-119 (1995).		
13.	Bullard et al., <i>In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies</i> , J Neurosurg 64:257-262 (1986).		
14.	Bullard et al., <i>Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs)</i> , Nuklearmedizin-Nuclear Med, 25:210-215 (1986).		
15.	Folkman, J, <i>Anti-angiogenesis: new concept for therapy of solid tumors</i> , Ann. Surg., 175:409-416 (1972).		
16.	Forsberg et al., <i>Skin wounds and severed nerves heal normally in mice lacking tenascin-C</i> , Proc Natl Acad Sci USA, 93:6594-6599 (1996).		
17.	Harris et al., <i>A revised European-American classification of lymphoid neoplasms: A proposal form the International Lymphoma Study Group</i> , Blood:1361-1392 (1994).		
18.	Harris et al., <i>Growth factors and angiogenesis in breast cancer</i> , Recent Results in Cancer Research, 127:35-41 (1993).		
19.	He et al., <i>Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin</i> , J. Neuroimmunol., 52:127-137 (1994).		
20.	Hettasch et al., <i>Tissue transglutaminase expression in human breast cancer</i> . Lab. Invest., 75:637-645 (1996).		
21.	Huse, M., <i>Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda</i> , Science, 246:1275-1281 (1989).		
22.	Jahkola et al., <i>Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis</i> , Int J Cancer, 69:445-447 (1996).		
23.	Jallo et al., <i>Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis</i> , Neurosurgery, 41:1052-1059 (1997).		
24.	Kawakatsu et al., <i>Human carcinoma cells synthesize and secrete tenascin in vitro</i> , Jpn J Cancer Res. 83:1073-1080 (1992).		
25.	Kojima et al., <i>Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells</i> , J Cell Biol., 121:439-448 (1993).		
26.	Kostianovsky et al., <i>Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions</i> , Ultrastructural Pathol, 21:537-544 (1997).		
27.	Kusagawa et al., <i>Expression and degradation of tenascin-C in human lung cancers</i> , British J Cancer, 77:98-102 (1998).		
28.	Mackie EJ, <i>Molecules in focus: tenascin-C</i> , Int J Biochem Cell Biol, 29:1133-1137 (1997).		
29.	Mackie et al., <i>Regulation of tenascin-C expression in Bone Cells by TGF-β</i> , Bone, 22:301-307 (1998).		
30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, <i>National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas</i> , Cancer, 49:2112-2135 (1982).		
31.	Reist et al., <i>Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent</i> , Clinical Cancer Research., 4:2495-2502 (1998).		
32.	Ribatti et al., <i>Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study</i> , Eur J. Haematology, 56:45-53 (1996).		

EXAMINER

Amitha R

DATE CONSIDERED

6/28/2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

Ambari

DATE CONSIDERED

6/28/2004

***EXAMINER** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/008,062
		Filing Date	October 19, 2001
		First Named Inventor	David Rizzieri
		Group Art Unit	1619 1642
		Examiner Name	Unknown A.M. Harris JUN 20 2002
Sheet	1	of	1
		Attorney Docket Number	5405.252 TECH CENTER 1600/2000

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
amh	1	5,624,659		Bigner et al.	4/29/1997	

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	6/28/2004
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.